###begin article-title 0
Does Plasminogen Activator Inhibitor-1 Drive Lymphangiogenesis?
###end article-title 0
###begin p 1
Conceived and designed the experiments: JMF AN. Performed the experiments: FB LML BD AM. Analyzed the data: FB SB AM JL CM AN. Contributed reagents/materials/analysis tools: SB JL VL CM GHH LRL JMF AN. Wrote the paper: FB AN.
###end p 1
###begin p 2
###xml 666 672 <span type="species:ncbi:10090">murine</span>
###xml 737 741 <span type="species:ncbi:10090">mice</span>
###xml 972 987 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1063 1088 <span type="species:ncbi:11757">mouse mammary tumor virus</span>
###xml 1120 1124 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
The purpose of this study is to explore the function of plasminogen activator inhibitor-1 (PAI-1) during pathological lymphangiogenesis. PAI-1, the main physiological inhibitor of plasminogen activators is involved in pathological angiogenesis at least by controlling extracellular proteolysis and by regulating endothelial cell survival and migration. Protease system's role in lymphangiogenesis is unknown yet. Thus, based on its important pro-angiogenic effect, we hypothesized that PAI-1 may regulate lymphangiogenesis associated at least with metastatic dissemination of cancer cells. To address this issue, we studied the impact of PAI-1 deficiency in various murine models of tumoral lymphangiogenesis. Wild-type PAI-1 proficient mice were used as controls. We provide for the first time evidence that PAI-1 is dispensable for tumoral lymphangiogenesis associated with breast cancers either induced by mammary carcinoma cell injection or spontaneously appearing in transgenic mice expressing the polyomavirus middle T antigen (PymT) under the control of a mouse mammary tumor virus long-terminal repeat promoter (MMTV-LTR). We also investigated inflammation-related lymphatic vessel recruitment by using two inflammatory models. PAI-1 deficiency did neither affect the development of lymphangioma nor burn-induced corneal lymphangiogenesis. These novel data suggest that vascular remodelling associated with lymphangiogenesis and angiogenesis involve different molecular determinants. PAI-1 does not appear as a potential therapeutic target to counteract pathological lymphangiogenesis.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 380 383 380 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-Karpanen1">[1]</xref>
###xml 963 966 963 966 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-Thiele1">[2]</xref>
###xml 1108 1111 1108 1111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-Thaunat1">[3]</xref>
###xml 954 962 <span type="species:ncbi:9606">patients</span>
The lymphatic network is composed of blind-ended lymphatic vessels that regulate tissue homeostasis, the afferent immune response and fat transport. After collecting extravasated protein-rich fluid and lymphocytes from the extracellular space or triglycerides from the gut, lymphatic capillaries transport them back to the blood circulation through larger vessels and lymph nodes [1]. Tumoral cell metastasis may occur by invading either the blood circulation or the lymphatic vascular system. The increased permeability and the absence of basement membrane of lymphatic vessels compared to blood vessels facilitate the intravasation of tumor cells into the lymphatic system. Therefore, lymphatic vessels offer an easy way for cancer cells to disseminate and form metastasis into the lymph nodes before reaching the blood circulation. This is supported by the clinical investigation of the sentinel lymph node while searching for cancer dissemination in patients [2]. Moreover, the lymphatic system is involved in chronic inflammatory diseases and in transplant rejection (renal and corneal graft rejection) [3]. Therefore, a better understanding of the molecular and cellular basis of lymphatic abnormalities associated with cancers and inflammation is essential for the development of novel therapeutic strategies.
###end p 4
###begin p 5
###xml 158 161 158 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-Dass1">[4]</xref>
###xml 561 564 561 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-Lee1">[5]</xref>
###xml 643 646 643 646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-Dano1">[6]</xref>
###xml 763 766 763 766 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-Czekay1">[7]</xref>
###xml 844 847 844 847 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-Bajou1">[8]</xref>
###xml 972 975 972 975 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-Leik1">[9]</xref>
###xml 976 980 976 980 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-Lambert2">[14]</xref>
###xml 1034 1038 1034 1038 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-Ossowski1">[15]</xref>
###xml 1040 1044 1040 1044 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-Tsuchiya1">[16]</xref>
###xml 1202 1206 1202 1206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-Lambert2">[14]</xref>
###xml 1208 1212 1208 1212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-Devy1">[17]</xref>
###xml 1213 1217 1213 1217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-Bajou3">[19]</xref>
###xml 1423 1426 1423 1426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-Lee1">[5]</xref>
###xml 1637 1641 1637 1641 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-Lambert1">[11]</xref>
###xml 1643 1647 1643 1647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-Lambert2">[14]</xref>
###xml 1370 1377 <span type="species:ncbi:9606">patient</span>
Components of the plasminogen activation system are involved in several physiological and pathological processes associated with important tissue remodelling [4]. This proteolytic system is composed of serine proteases including tissue-type plasminogen activator (tPA), urokinase-type plasminogen activator (uPA), uPA receptor (uPAR) and the plasminogen activator inhibitors (PAI), the main one being PAI-1. The contribution of these proteins in cancer progression relies on their capacity to control various biological processes such as (i) cell proliferation [5]; (ii) cell invasion through plasmin-mediated extracellular matrix degradation [6]; (iii) cell adhesion and migration through the interaction of uPA/uPAR/PAI-1 complex with vitronectin and integrins [7]; and (iv) cell apoptosis through the control of pro-apoptotic factor release [8]. PAI-1 is now recognized as an essential factor of the host microenvironment that promotes tumor growth, vessel recruitment [9]-[14] and dissemination of tumoral cells to distant organs [15], [16]. The effect of PAI-1 depends on its concentration, being pro-angiogenic at physiological concentration and anti-angiogenic at pharmacological concentrations [14], [17]-[19] These experimental observations confirm the positive correlation existing between PAI-1 blood levels, the rate of metastasis and the poor prognostic of patient with different types of cancers (for review: [5]). The essential role of PAI-1 in angiogenesis was also demonstrated in a laser-induced model of choroidal angiogenesis that mimics the age-related macular degeneration extending its function to ocular diseases [11], [14].
###end p 5
###begin p 6
###xml 284 288 <span type="species:ncbi:10090">mice</span>
Based on its pivotal role during tumoral angiogenesis, a contribution of PAI-1 in lymphangiogenesis is anticipated, but not documented. In the present study, to address this issue, we applied different models of tumoral and inflammation-induced lymphangiogenesis into PAI-1 deficient mice having different genetic backgrounds.
###end p 6
###begin title 7
Methods
###end title 7
###begin title 8
###xml 20 24 <span type="species:ncbi:10090">Mice</span>
Transgenic Modified Mice
###end title 8
###begin p 9
###xml 38 41 38 41 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 216 219 216 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-Bajou1">[8]</xref>
###xml 221 225 221 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-Devy1">[17]</xref>
###xml 227 231 227 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-Jost1">[20]</xref>
###xml 299 302 299 302 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 386 390 386 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-Maillard1">[10]</xref>
###xml 392 396 392 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-Jost1">[20]</xref>
###xml 518 521 518 521 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 615 619 615 619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-Almholt1">[21]</xref>
###xml 27 31 <span type="species:ncbi:10090">mice</span>
###xml 77 81 <span type="species:ncbi:10090">mice</span>
###xml 269 273 <span type="species:ncbi:10090">mice</span>
###xml 427 431 <span type="species:ncbi:10090">mice</span>
###xml 542 546 <span type="species:ncbi:10090">mice</span>
###xml 621 626 <span type="species:ncbi:10090">Mouse</span>
Homozygous PAI-1 deficient mice (PAI-1-/-) and their corresponding wild type mice (PAI-1 WT) were those previously used for angiogenesis studies with a mixed genetic background of 87% C57BL/6 and 13% 129SV/SL strain [8], [17], [20]. Their corresponding immunodeficient mice were generated in a RAG-1-/- background and genotyped by PAI-1 and PGKPA gene annealing as previously described [10], [20]. Heterozygous FVB/N-PyMT male mice obtained from Finsen Laboratory (Copenhagen, Denmark) were mated with homozygous PAI-1-/- and PAI-1 WT female mice, which were backcrossed for eight generations into the FVB/N strain [21]. Mouse experimentation was done in accordance to the guidelines of the University of Liege regarding the care and use of laboratory animals.
###end p 9
###begin title 10
Cell Lines
###end title 10
###begin p 11
###xml 214 218 214 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-Karpanen2">[22]</xref>
###xml 566 592 566 592 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">TTG-TTC-GCT-GCC-TGA-CAC-TG</named-content>
###xml 618 644 618 644 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">CTC-TCT-CTC-AAG-GCC-CCA-AA</named-content>
###xml 4 9 <span type="species:ncbi:9606">human</span>
###xml 67 72 <span type="species:ncbi:9606">human</span>
###xml 424 430 <span type="species:ncbi:9913">bovine</span>
###xml 760 765 <span type="species:ncbi:9606">Human</span>
The human MCF-7 breast carcinoma cell line transfected either with human VEGF-C mature form cDNA (MCF-7/VEGF-C) or with control cDNA (MCF-7/EB57II) were obtained from Kari Alitalo (University of Helsinki, Finland) [22]. Cells were routinely cultured in RPMI-1640 medium (Invitrogen, Carlsbad, CA) supplemented with GlutaMAX, 25 mM Hepes, penicillin (100 U/ml), streptomycin (100 mg/ml), hygromycin (150 mg/ml) and 10% fetal bovine serum (Gibco, Grand Island, NY). Amplification of VEGF-C cDNAs was carried out by polymerase chain reaction using the reverse primers: TTG-TTC-GCT-GCC-TGA-CAC-TG and the forward primers: CTC-TCT-CTC-AAG-GCC-CCA-AA. The PCR condition was 94degreesC for 0.15 min, 55degreesC for 0.2 min, and 72degreesC for 0.2 min, for 30 cycles. Human VEGF-C ELISA (R&D Systems, Minneapolis, MN) was performed on medium conditioned by cells according manufacture's instructions.
###end p 11
###begin title 12
Mammary Orthotopic Transplantation
###end title 12
###begin p 13
###xml 125 126 125 126 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 240 243 236 239 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 258 261 254 257 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 538 539 532 533 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 541 542 535 536 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 543 546 537 540 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3/2</sup>
###xml 546 550 540 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-Mattila1">[23]</xref>
###xml 269 273 <span type="species:ncbi:10090">mice</span>
###xml 275 279 <span type="species:ncbi:10090">Mice</span>
###xml 568 572 <span type="species:ncbi:10090">mice</span>
###xml 881 885 <span type="species:ncbi:10090">mice</span>
Subconfluent MCF7 cultures were harvested by trypsinization, washed twice and resuspended in serum-free medium. Cells (2.5x106/50 microl) were bilaterally inoculated into the fat pads of the fifth mammary glands (mfp) of 8- to 12-week-PAI-1-/- and, -WT RAG-1-/- female mice. Mice were supplemented with a subcutaneous 60-days slow-release pellet containing 0.72 mg of 17ss-estradiol (Innovative Research of America, Toledo, OH). Tumor growth was measured with a calliper and the volume was calculated according to the formula V = (pi/6)(d1Xd2)3/2[23]. After 16 weeks, mice were killed and tumors, lungs and lymph nodes were collected. All the samples were formalin fixed and paraffin embedded. The tumor incidence is defined as the percentage of animals bearing a palpable tumor. Two separate sets of experiments with similar results were performed with each time at least 8 to 11 mice per experimental group; presented data are combined results (34-38 injected mammary fat pads (mfp) per condition).
###end p 13
###begin title 14
###xml 25 29 <span type="species:ncbi:10090">Mice</span>
Tumor Processing in PyMT Mice
###end title 14
###begin p 15
###xml 617 620 617 620 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 695 698 695 698 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 777 780 777 780 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 7 11 <span type="species:ncbi:10090">mice</span>
###xml 156 160 <span type="species:ncbi:10090">mice</span>
###xml 517 521 <span type="species:ncbi:10090">mice</span>
###xml 537 541 <span type="species:ncbi:10090">mice</span>
###xml 591 595 <span type="species:ncbi:10090">mice</span>
###xml 621 625 <span type="species:ncbi:10090">mice</span>
###xml 670 674 <span type="species:ncbi:10090">mice</span>
###xml 699 703 <span type="species:ncbi:10090">mice</span>
###xml 751 755 <span type="species:ncbi:10090">mice</span>
Female mice heterozygous for the PyMT transgene and homozygous for the wild type or mutated PAI-1 gene were used in these studies. After 8, 11 or 14 weeks, mice were killed and tumors, lungs and lymph nodes were collected. Tumors were weighted before formalin fixation and paraffin embedding. To avoid any variance from the fat pad localisation (peritoneal-localised tumors being bigger than those developed in the thoracic cavity), all the individual tumor weights were summed to give the total tumor weight of each mice. The number of mice sacrified per genotype was: 19 for PyMT PAI-1 WT mice and 23 for PyMT PAI-1-/- mice sacrified at 14 weeks; 17 for PyMT PAI-1 WT mice and 9 for PyMT PAI-1-/- mice sacrified at 11 weeks and 12 for PyMT PAI-1 WT mice, and 7 for PyMT PAI-1-/- sacrified at 8 weeks.
###end p 15
###begin title 16
Lymphangioma
###end title 16
###begin p 17
###xml 137 141 137 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-Mancardi1">[24]</xref>
###xml 363 367 <span type="species:ncbi:10090">mice</span>
Lymphatic endothelial hyperplasia (lymphangioma) formation was induced by two intraperitoneal injections of incomplete Freund's adjuvant [24]. For ethical purposes, buprenorphine hydrochloride injections (0.05 mg/kg, TEMGESIC(R), Reckitt Benckiser, UK) were administered every 12 h during the first 5 days 1 h before and after adjuvant injections. After 4 weeks, mice (n = 6) were killed and lymphangioma masses appearing at the surface of diaphragm were photographed for quantification using the ImageJ 1.40 g software (NIH). The lymphangioma development was determined by reporting the lymphangioma surface on the total organ area. The lymphatic origin of tumors was assessed by positivity for LYVE-1 as described above. Sirius Red staining was obtained by incubating the deparaffinised and ionised slides with 0.1% Sirius Red (Polyscience, Warrington, PA)/picric acid (1.15 g/100 ml). Slides were then rapidly incubated in 90% alcohol and in xylene before being mounted with Eukitt medium.
###end p 17
###begin title 18
Immunohistochemistry on Slides and Metastasis Detection
###end title 18
###begin p 19
###xml 45 52 45 52 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0009653-t001">Table 1</xref>
###xml 237 238 233 234 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 239 240 235 236 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 242 243 238 239 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
All reagents and procedure are summarized in Table 1. In brief, after deparaffination and rehydration, immunostainings were performed on 6 microm slides by first unmasking antigens and subsequently blocking endogenous peroxidases by 3% H2O2/H2O for 20 min. Nonspecific binding was prevented by a specific treatment before the incubation with primary and secondary (if needed) antibodies followed by incubation with a streptavidin/HRP complex (DAKO, Glostrup, Denmark, 1/500) at room temperature (RT) for 30 min. Slides were stained with 3-3'diaminobenzidine hydrochloride (DAKO, Glostrup, Denmark) for 3 min to 10 min, counterstained with hematoxylin and mounted with Eukitt medium for microscope observation. Omission of the first antibody served as negative control.
###end p 19
###begin title 20
Antibodies and procedure used for immunochemistry to detect metastasis on lung and lymph node slides, lymphatic vessels and inflammatory cells on primary tumors/lymphangiomas.
###end title 20
###begin p 21
RT = Room temperature.
###end p 21
###begin p 22
###xml 117 124 117 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0009653-t001">Table 1</xref>
###xml 46 50 <span type="species:ncbi:10090">mice</span>
###xml 79 83 <span type="species:ncbi:10090">mice</span>
Metastases in the lymph nodes and in lungs of mice bearing MCF7 tumors or PyMT mice were detected by immunostaining (Table 1). Results are expressed as the percentage of animals presenting at least one metastatic nodule.
###end p 22
###begin title 23
Computerized Vessel Quantification in Tumors and Lymphangioma
###end title 23
###begin p 24
###xml 347 348 343 344 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 355 356 347 348 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 454 455 442 443 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 546 547 530 531 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 723 724 703 704 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
ImageJ software (NIH) was used to first manually delineate the immunolabelled vessels. We binarized images and optimized the threshold to highlight the vessels. For mammary tumors, the following parameters were determined on the whole tumor section: the relative vascular area (lymphatic vessel area reported to the total area of the tumor (microm2/microm2)), the number of sections of lymphatic vessels (reported to the total area of the tumor (1/microm2)) and the mean vessel area (lymphatic vessel area divided by the number of vessels (microm2)). For lymphangiomas, due to the variation in lymphangioma width associated with different fibrotic reaction, vessel quantifications are expressed by total vessel area (microm2) (at least 3 images were analyzed per sample (n = 6)).
###end p 24
###begin title 25
Corneal Assay
###end title 25
###begin p 26
###xml 1096 1097 1092 1093 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1343 1347 1339 1343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-Fenton1">[25]</xref>
###xml 1628 1632 1624 1628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-Blacher1">[26]</xref>
###xml 181 185 <span type="species:ncbi:10090">mice</span>
###xml 278 282 <span type="species:ncbi:10090">mice</span>
###xml 446 452 <span type="species:ncbi:9986">rabbit</span>
###xml 596 601 <span type="species:ncbi:9823">swine</span>
###xml 607 613 <span type="species:ncbi:9986">rabbit</span>
Corneal lymphangiogenesis was induced by thermal cauterization of the central cornea by using an ophthalmic cautery (OPTEMP II V, Alcon Surgial, Fort Worth, USA). Seven days later, mice were sacrificed, eyes were removed and corneas were flat mounted (n = 5, one flat mount per mice). Whole corneas were stained after fixation in ethanol 70%. Cornea whole mounts were blocked in 1,5% BSA-3% Gloria milk for 1 h at RT and incubated overnight with rabbit anti-LYVE-1 (1/600, a kind gift from Dr. K. Alitalo, Finland). After four 10 min washes with PBS, corneas were incubated with the FITC-coupled swine anti-rabbit Ig (1/40; DAKO, Glostrup, Denmark) for 60 min at RT and whole-mounted on a microscope slide with Vectashield-DAPI mounting medium (Vector Laboratories, Burlingame, CA). The area covered by immunostained lymphatic vessels was determined and normalized to the total corneal area. We also measured the length densities defined as the total area occupied by lymphatic network and the cumulative length of vessels. For both parameters, results are expressed per corneal area unit (microm2). As the mechanism of vascular growth is sprouting, its extent can be detected by the increase of vessel network extremities, which corresponds to the number of smallest vessels (so-called first order vessels in the centripetal ordering method) [25]. To achieve this, we determined the end-point density defined as the vessel network extremity number per corneal area unit. The branching density (defined as the vessel branching number per corneal area unit) was also measured to evaluate the degree of the vessel tree complexity [26].
###end p 26
###begin title 27
Statistical Analysis
###end title 27
###begin p 28
###xml 449 450 447 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Statistical analyses were performed using GraphPad PRISM 4 software. Incidences were evaluated as contingency table by Fisher's exact test. Other variables were tested by a one-way ANOVA (Kruskal-Wallis test) followed by the Mann Whitney test in order to avoid multiplicity. These tests were also used to determine significance in the morphometric analyses. Results are expressed +/- S.E.M. Differences were considered statistically significant for P values less than or equal to 0.05.
###end p 28
###begin title 29
Results
###end title 29
###begin title 30
PAI-1 Is Dispensable for Lymphangiogenesis in an Experimental Model of Breast Cancer
###end title 30
###begin p 31
###xml 214 217 214 217 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 257 260 257 260 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 358 365 358 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009653-g001">Fig. 1A</xref>
###xml 699 702 699 702 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 778 779 778 779 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 790 791 790 791 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 814 821 814 821 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009653-g001">Fig. 1B</xref>
###xml 883 884 883 884 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 895 902 895 902 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009653-g001">Fig. 1C</xref>
###xml 1333 1339 1333 1339 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">versus</italic>
###xml 1352 1355 1352 1355 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1363 1364 1363 1364 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1431 1437 1431 1437 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">versus</italic>
###xml 1449 1452 1449 1452 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1460 1467 1460 1467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009653-g001">Fig. 1B</xref>
###xml 1585 1588 1585 1588 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1595 1602 1595 1602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009653-g001">Fig. 1C</xref>
###xml 218 222 <span type="species:ncbi:10090">mice</span>
###xml 414 418 <span type="species:ncbi:10090">Mice</span>
###xml 609 613 <span type="species:ncbi:10090">mice</span>
###xml 703 707 <span type="species:ncbi:10090">mice</span>
###xml 840 844 <span type="species:ncbi:10090">mice</span>
###xml 909 913 <span type="species:ncbi:10090">mice</span>
###xml 1098 1102 <span type="species:ncbi:10090">mice</span>
###xml 1328 1332 <span type="species:ncbi:10090">mice</span>
###xml 1356 1360 <span type="species:ncbi:10090">mice</span>
###xml 1426 1430 <span type="species:ncbi:10090">mice</span>
###xml 1453 1457 <span type="species:ncbi:10090">mice</span>
###xml 1589 1593 <span type="species:ncbi:10090">mice</span>
To test the impact of PAI-1 on lymphatic vessel recruitment in tumors, VEGF-C-overexpressing MCF7 cells or control MCF7 cells were bilaterally injected into the fifth mammary fat pads (mfp) of immunodeficient RAG-1-/- mice that are deficient in PAI-1 (PAI-1-/-) or not (PAI-1 WT). We checked the production of VEGF-C by the tumor cells in culture by RT-PCR (Fig. 1A) and in supernatants by ELISA (data not shown). Mice were supplemented with oestrogen by the subcutaneous implantation of oestradiol releasing pellets. Two separate sets of experiments with similar results were performed with at least 8 to 10 mice per experimental group (34-38 mfp per condition). At week 16, both PAI-1 WT and PAI-1-/- mice implanted with VEGF-C expressing cells showed higher tumor incidence (P = 0.0051, P<0.0001, respectively; Fig. 1B) and, in PAI-1 WT mice, a tendency to a higher tumor volume (P = 0.1513; Fig. 1C) than mice inoculated with mock MCF7 cells. It is worth noting that the effect of VEGF-C on tumoral volume didn't reached the statistical significance due to the low number of tumors detected in mice injected with the non-VEGF-C producing cells (3 out of 38 mfp). Interestingly, PAI-1 deficiency reduced the incidence of tumors developed both in the presence of VEGF-C expression (52% of VEGF-C expressing tumors in PAI-1 WT mice versus 22% in PAI-1-/- mice) (P<0.0089) and in its absence (8% of control tumors in PAI-1 WT mice versus 0% in PAI-1-/- mice) (Fig. 1B). When considering the volume of tumors, differences did not reach statistical differences between PAI-1 WT and PAI-1-/- mice (Fig. 1C).
###end p 31
###begin title 32
###xml 163 166 163 166 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 167 171 <span type="species:ncbi:10090">mice</span>
Tumor development after orthotopic injection of VEGF-C overexpressing MCF7 cells or control MCF7 cells implanted in the mammary fat pads (mfp) of PAI-1 WT or PAI-1-/- mice.
###end title 32
###begin p 33
###xml 205 212 205 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s2">Methods</xref>
###xml 479 483 <span type="species:ncbi:10090">mice</span>
(A): RT-PCR analysis of VEGF-C and 28S mRNA expression by MCF7. (B): Tumor incidence (%) is defined as the percentage of palpable tumor per mfp. (C): Tumor volume was measured as described in Material and Methods. (D): Representative figure of a typical metastasis in lymph node (left) and lung (right). (E): Percentage of animal bearing at least a tumor nodule (metastasis% detected in lymph nodes (black boxes) and lungs (white boxes). Number of mfp per condition = 34-38. The mice PAI-1 status (WT or -/-) and the VEGF-C production (VEGF-C) or not (Ctl) by MCF7 cells are indicated below each graph. Data are +/- S.E.M. Scale bars: 200 microm. ** P</=0.01, *** P</=0.001, NS = Non Significant.
###end p 33
###begin p 34
###xml 247 248 247 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 279 280 279 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 418 421 418 421 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 429 439 429 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009653-g001">Fig. 1D, E</xref>
###xml 294 298 <span type="species:ncbi:10090">mice</span>
###xml 422 426 <span type="species:ncbi:10090">mice</span>
The metastatic ability of cells was assessed by immunochemical staining with antibodies raised against pS2 protein and cytokeratin WSS on lymph node sections or against pS2 protein and Ki-67 on lung sections. Histological examination in the lung (P = 0.2879) or the lymph nodes (P = 0.1037) of mice bearing a VEGF-C expressing tumor revealed similar metastasis incidence for the two different groups (PAI-1 WT or PAI-1-/- mice) (Fig. 1D, E).
###end p 34
###begin p 35
###xml 67 74 67 74 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009653-g002">Fig. 2A</xref>
###xml 234 247 234 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009653-g002">Fig. 2B, C, D</xref>
###xml 283 287 283 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-Mattila1">[23]</xref>
###xml 468 471 468 471 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 478 479 478 479 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 491 498 491 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009653-g002">Fig. 2B</xref>
###xml 639 642 639 642 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 820 827 820 827 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009653-g002">Fig. 2C</xref>
###xml 862 869 862 869 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009653-g002">Fig. 2D</xref>
###xml 472 476 <span type="species:ncbi:10090">mice</span>
###xml 606 610 <span type="species:ncbi:10090">mice</span>
###xml 643 647 <span type="species:ncbi:10090">mice</span>
The lymphatic vasculature was next investigated on primary tumors (Fig. 2A). Through Lyve-1 immunolabeling on tumor sections, quantification performed by computerized image analysis led to the determination of 3 different parameters (Fig. 2B, C, D). In accordance to previous report [23], VEGF-C over-expressing tumors displayed a higher relative vasculature area than control tumors. However, the VEGF-C-induced lymphatic vasculature was similar in PAI-1 WT and PAI-1-/- mice (P = 0.4048) (Fig. 2B). Because of the very low number of tumors developed in the absence of VEGF-C (3 out of 38 mfp in PAI-1 WT mice and 0 out of 34 mfp in PAI-1-/- mice), no comparison could be performed between the two genotypes. This increased lymphatic vessel area observed in the presence of VEGF-C relied on an increased vessel number (Fig. 2C) while vessel size was unchanged (Fig. 2D).
###end p 35
###begin title 36
###xml 197 200 197 200 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 201 205 <span type="species:ncbi:10090">mice</span>
Analysis of intratumoral lymphatic vessels in tumors induced by orthotopic injection of VEGF-C overexpressing MCF7 or control MCF7 cells implanted in the mammary fat pads (mfp) of PAI-1 WT or PAI-1-/- mice.
###end title 36
###begin p 37
###xml 165 168 165 168 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 130 134 <span type="species:ncbi:10090">mice</span>
###xml 136 138 <span type="species:ncbi:10090">WT</span>
###xml 159 163 <span type="species:ncbi:10090">mice</span>
###xml 577 581 <span type="species:ncbi:10090">mice</span>
###xml 596 598 <span type="species:ncbi:10090">WT</span>
(A): Representative images of Lyve-1 positive-vessels at two different magnifications in VEGF-C expressing tumors developed in WT mice (WT) or PAI-1 deficient mice (-/-), and in control tumors (Ctl). (B-D): Quantification of lymphatic vessels has been performed by computerized image analysis and led to the determination of three parameters: 1- relative vascular area (area occupied by intratumoral lymphatic vessels reported to the total tumor surface) (B); 2- number of lymphatic vessel sections per slide (number of vessels) (C) and; 3- mean lymphatic vessel size (D). The mice PAI-1 status (WT or -/-) and the VEGF-C production (VEGF-C) or not (Ctl) by MCF7 cells are indicated below each graph. Data are +/- S.E.M. NS = Non Significant.
###end p 37
###begin title 38
PAI-1 Is Dispensable for Lymphangiogenesis and Metastatic Dissemination in a Spontaneous Model of Breast Tumors
###end title 38
###begin p 39
###xml 209 212 209 212 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 337 338 337 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 349 356 349 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009653-g003">Fig. 3A</xref>
###xml 449 450 449 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 664 667 664 667 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 699 706 699 706 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009653-g003">fig. 3B</xref>
###xml 824 827 824 827 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 842 843 842 843 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 949 952 949 952 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 959 960 959 960 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 116 120 <span type="species:ncbi:10090">mice</span>
###xml 169 173 <span type="species:ncbi:10090">mice</span>
###xml 198 200 <span type="species:ncbi:10090">WT</span>
###xml 213 217 <span type="species:ncbi:10090">mice</span>
###xml 443 447 <span type="species:ncbi:10090">mice</span>
###xml 647 649 <span type="species:ncbi:10090">WT</span>
###xml 668 672 <span type="species:ncbi:10090">mice</span>
###xml 793 795 <span type="species:ncbi:10090">WT</span>
###xml 796 800 <span type="species:ncbi:10090">mice</span>
###xml 828 832 <span type="species:ncbi:10090">mice</span>
###xml 910 912 <span type="species:ncbi:10090">WT</span>
###xml 913 917 <span type="species:ncbi:10090">mice</span>
###xml 953 957 <span type="species:ncbi:10090">mice</span>
In order to further analyse the role of PAI-1 in tumor growth and metastatic dissemination, we used transgenic PyMT mice that spontaneously develop mammary tumors. PyMT mice were crossed with PAI-1 WT or PAI-1-/- mice in a FVB/N background. At week 8 or 11, difference was observed neither in tumor incidence (100%) nor in tumor weight (P = 0.8875; Fig. 3A). A very slight increase of tumor weight was even observed after 14 weeks in PAI-1 KO mice (P = 0.0461). Histochemical and immunochemical analyses detecting cytokeratin 8 and Ki67 did not reveal any difference in the metastatic dissemination into the lung or lymph nodes between PyMT PAI-1 WT and PyMT PAI-1-/- mice sacrified after 14 weeks (fig. 3B). Indeed, metastatic nodules were detected in the lung of 63.1% (12/19) of PyMT PAI-1 WT mice and 52.2% of PymT PAI-1-/- mice (12/23) (P = 0.5421). Similarly, lymph nodes of 73,68% (14/19) of PyMT PAI-1 WT mice and 47,8% (11/23) of PymT PAI-1-/- mice (P = 0.1203) were infiltrated by tumoral cells.
###end p 39
###begin title 40
###xml 94 97 94 97 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 59 63 <span type="species:ncbi:10090">mice</span>
###xml 83 85 <span type="species:ncbi:10090">WT</span>
###xml 98 102 <span type="species:ncbi:10090">mice</span>
Primary tumor development and metastatic potential of PyMT mice crossed with PAI-1 WT or PAI-1-/- mice.
###end title 40
###begin p 41
###xml 161 164 161 164 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 292 295 292 295 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 347 350 347 350 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 43 47 <span type="species:ncbi:10090">mice</span>
###xml 149 151 <span type="species:ncbi:10090">WT</span>
###xml 165 169 <span type="species:ncbi:10090">mice</span>
###xml 272 274 <span type="species:ncbi:10090">WT</span>
###xml 301 305 <span type="species:ncbi:10090">mice</span>
###xml 328 330 <span type="species:ncbi:10090">WT</span>
###xml 356 360 <span type="species:ncbi:10090">mice</span>
Presented results are from 11- and 14-week mice. (A): Tumor weight and (B): podoplanin positive relative surface in primary tumors observed in PAI-1 WT and PAI-1-/- mice. (C): Percentage of metastasis in lymph nodes (black columns) and lungs (white columns). n = 16 PAI-1 WT-PyMT and 17 PAI-1-/--PyMT mice at 14 weeks, 17 PAI-1 WT-PyMT and 9 PAI-1-/--PyMT mice at 11 weeks. Data are +/- S.E.M. *P</=0.05, NS = Non Significant.
###end p 41
###begin p 42
###xml 136 140 136 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-Henno1">[27]</xref>
###xml 261 262 261 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 274 281 274 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009653-g003">Fig. 3C</xref>
In order to quantify the lymphatic vasculature inside primary PyMT tumors, a computer-assisted automatic quantification method was used [27]. No difference in terms of podoplanin labelling was observed between tumors generated in both genotypes after 14 weeks (P = 0.0945) (Fig. 3C).
###end p 42
###begin title 43
PAI-1 Deficiency Does Not Affect Inflammation-Related Lymphangiogenesis
###end title 43
###begin p 44
###xml 178 182 178 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-Mancardi1">[24]</xref>
###xml 212 215 212 215 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 559 560 559 560 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 567 574 567 574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009653-g004">Fig. 4A</xref>
###xml 989 992 989 992 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1035 1036 1035 1036 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1045 1052 1045 1052 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009653-g004">Fig. 4B</xref>
###xml 1209 1210 1203 1204 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1240 1241 1228 1229 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1250 1253 1238 1241 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1255 1256 1243 1244 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1318 1319 1300 1301 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1355 1356 1331 1332 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1365 1368 1341 1344 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1370 1371 1346 1347 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1405 1408 1381 1384 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1568 1569 1544 1545 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1578 1585 1554 1561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009653-g004">Fig. 4C</xref>
###xml 1668 1671 1644 1647 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1678 1679 1654 1655 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1686 1693 1662 1669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009653-g004">Fig. 4D</xref>
###xml 192 194 <span type="species:ncbi:10090">WT</span>
###xml 224 228 <span type="species:ncbi:10090">mice</span>
###xml 245 249 <span type="species:ncbi:10090">mice</span>
###xml 1029 1033 <span type="species:ncbi:10090">mice</span>
###xml 1220 1222 <span type="species:ncbi:10090">WT</span>
###xml 1329 1331 <span type="species:ncbi:10090">WT</span>
###xml 1409 1413 <span type="species:ncbi:10090">mice</span>
###xml 1672 1676 <span type="species:ncbi:10090">mice</span>
###xml 1793 1797 <span type="species:ncbi:10090">mice</span>
In order to explore PAI-1 impact on the lymphatic vessel recruitment in inflammatory conditions, we applied a model of lymphatic endothelial cell hyperplasia called lymphangioma [24] to PAI-1 WT (n = 6) and PAI-1-/- (n = 6) mice. After 4 weeks, mice were sacrified and the lymphangiomas that appeared as white masses underneath the diaphragm were measured. The surface of lymphangioma area was reported to the total area of the organ (percentage of invasion). Macroscopical analyses revealed that the lymphangioma surface was decreased with PAI-1 deficiency (P<0.01, Fig. 4A). Immunohistochemical analyses of these lymphangiomas were assessed with Lyve-1 and CD45 antibodies to label lymphatic vessels and inflammatory cells, respectively. Fibrosis was evaluated through Sirius red staining. Quantification was performed by a semi-automatic computer-assisted method. The microscopical analyses of lymphangioma sections showed that the area covered by lymphatic vessels was similar in PAI-1-/- compared to corresponding wild type mice (P = 0.49, Fig. 4B). However, we pointed out differences in the lymphatic vessel structure between the experimental groups. The number of vessels per section was 54+/-5 microm2 in PAI-1 WT and 31+/-2 microm2 in PAI-1-/- (P = 0.0002), and the vessel average surface was 383+/-43 microm2 in PAI-1 WT and was 663+/-57 microm2 in PAI-1-/- (P = 0.0003). Thus, vessels in PAI-1-/- mice were fewer but larger leading to an equal vessel area than counterparts. No difference was detected regarding the surface occupied by inflammatory cells (P = 0.44, Fig. 4C). In sharp contrast, decrease of red Sirius stained fibrosis was observed in PAI-1-/- mice (P<0.01, Fig. 4D) and could explain the reduction of the lymphangioma area observed macroscopically in these mutant mice.
###end p 44
###begin title 45
###xml 48 51 48 51 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 37 39 <span type="species:ncbi:10090">WT</span>
###xml 52 56 <span type="species:ncbi:10090">mice</span>
Development of lymphangioma in PAI-1 WT or PAI-1-/- mice.
###end title 45
###begin p 46
###xml 59 62 59 62 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 78 80 <span type="species:ncbi:10090">WT</span>
A macroscopic decrease of lymphangioma is observed in PAI-1-/- as compared to WT (A). Similar recruitment of lymphatic vessels (assessed by Lyve-1 positivity) (B), and of CD45 positive-inflammatory cells (C) was observed in both genotypes. Evaluation of fibrosis was performed by Sirius red staining (D). Representative images are shown on the left and quantifications performed by computerized image analysis are shown on the right Data are +/- S.E.M (n = 6). Scale bars: A = 0.5 mm, B-D = 200 microm, ** P</=0.01.
###end p 46
###begin title 47
PAI-1 Is Dispensable for Corneal Lymphangiogenesis
###end title 47
###begin p 48
###xml 120 127 120 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 225 229 225 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-Cursiefen1">[28]</xref>
###xml 396 399 396 399 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 545 546 545 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 558 564 558 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009653-g005">Fig. 5</xref>
###xml 646 649 646 649 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 749 753 749 753 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-Blacher1">[26]</xref>
###xml 811 812 811 812 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 880 881 880 881 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 962 963 962 963 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 212 217 <span type="species:ncbi:10090">mouse</span>
###xml 400 404 <span type="species:ncbi:10090">mice</span>
###xml 439 443 <span type="species:ncbi:10090">mice</span>
###xml 635 637 <span type="species:ncbi:10090">WT</span>
###xml 650 654 <span type="species:ncbi:10090">mice</span>
We then extended our study to an additional model of lymphangiogenesis related to inflammation. The corneal assay is an in vivo model which consists in a neovascularization induced by burning the central area of mouse cornea [28]. We previously confirmed the presence of PAI-1 mRNA in corneal lesions (data not shown). No modification of the lymphatic vessel recruitment was observed in the PAI-1-/- mice (n = 5) compared to the wild type mice (n = 5) as assessed by the quantification of Lyve-1 labelled lymphatic vessels of the entire cornea (P = 0.3064) (Fig. 5). Structural features of the lymphatic network developed in the PAI-1 WT or PAI-1-/- mice were also similar since all parameters analysed by computerized image analysis were identical [26]: the end-point density reflecting the number of vessels (P = 0.2715), the node density representing the number of branchings (P = 0.4526) and the length density corresponding the total length of the vessels (P = 0.3998).
###end p 48
###begin title 49
###xml 112 115 112 115 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 101 103 <span type="species:ncbi:10090">WT</span>
###xml 116 120 <span type="species:ncbi:10090">mice</span>
Photography and quantification of the Lyve-1 positive-network observed in the corneal assay in PAI-1 WT or PAI-1-/- mice.
###end title 49
###begin p 50
###xml 371 378 371 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s2">Methods</xref>
The node, end-point and length densities are presented for both experimental groups with a schematic illustration of each of these measured parameters at the left. The area covered by the lymphatic vessels normalized to the total corneal area (relative surface, %) is also indicated. These parameters quantified by computerized image analysis are defined in Material and Methods. Data are +/- S.E.M (n = 5). Scale bar = 400 microm, NS = Non Significant.
###end p 50
###begin title 51
Discussion
###end title 51
###begin p 52
###xml 213 216 213 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-Leik1">[9]</xref>
###xml 218 222 218 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-Gutierrez1">[12]</xref>
###xml 224 228 224 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-McMahon1">[18]</xref>
###xml 244 248 244 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-Maillard1">[10]</xref>
###xml 250 254 250 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-Bajou2">[13]</xref>
###xml 289 293 289 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-Lambert1">[11]</xref>
###xml 295 299 295 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-Lambert2">[14]</xref>
###xml 664 668 664 668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-Bruyere1">[29]</xref>
###xml 739 746 739 746 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 764 771 764 771 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 129 133 <span type="species:ncbi:10090">mice</span>
###xml 948 952 <span type="species:ncbi:10090">mice</span>
The plasminogen activation system is largely implicated in pathological angiogenic processes. The genetic deficiency of PAI-1 in mice is associated to impaired blood vascularisation in several experimental models [9], [12], [18] such as cancer [10], [13] and choroidal angiogenesis models [11], [14]. The pivotal role of PAI-1 in pathological angiogenesis led to the expectation that this protease inhibitor regulates also lymphangiogenesis. Surprisingly, we previously reported that neither PAI-1 deficiency nor a pharmacological inhibitor of serine proteases directly affect the endothelial cell sprouting from thoracic duct explants in the lymphatic ring assay [29]. Nevertheless, this finding does not exclude a putative role of PAI-1 in vivo depending on the in vivo microenvironment and for instance, on an inflammatory reaction which is often associated with lymphangiogenesis. To address this important issue, we applied to PAI-1 deficient mice two models of breast cancer and two models of inflammation-related lymphangiogenesis. We found that PAI-1 is not essential for pathological lymphangiogenesis.
###end p 52
###begin p 53
###xml 160 164 160 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-Karpanen2">[22]</xref>
###xml 179 183 179 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-Mattila1">[23]</xref>
###xml 320 324 320 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-Mattila1">[23]</xref>
###xml 394 398 394 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-Skobe1">[30]</xref>
###xml 488 491 488 491 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 596 600 596 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-Karpanen2">[22]</xref>
###xml 602 606 602 606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-Mattila1">[23]</xref>
###xml 1129 1133 1129 1133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-Mattila1">[23]</xref>
###xml 1135 1139 1135 1139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-Skobe1">[30]</xref>
###xml 1158 1162 1158 1162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-Karpanen2">[22]</xref>
###xml 1171 1174 1171 1174 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1491 1495 1491 1495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-Aurora1">[31]</xref>
###xml 169 178 <span type="species:ncbi:10090">nude mice</span>
###xml 257 266 <span type="species:ncbi:10090">nude mice</span>
###xml 508 512 <span type="species:ncbi:10090">mice</span>
###xml 532 534 <span type="species:ncbi:10090">WT</span>
###xml 554 558 <span type="species:ncbi:10090">mice</span>
###xml 914 918 <span type="species:ncbi:10090">mice</span>
###xml 1119 1128 <span type="species:ncbi:10090">nude mice</span>
###xml 1153 1157 <span type="species:ncbi:10090">mice</span>
###xml 1175 1179 <span type="species:ncbi:10090">mice</span>
###xml 1213 1217 <span type="species:ncbi:10090">mice</span>
We first used a orthotopic graft model of VEGF-C overexpressing-mammary carcinoma cells (MCF7). VEGF-C has been indeed reported to promote tumor growth in SCID [22] and nude mice [23]. Tumor lymphangiogenesis was increased in VEGF-C MCF7 tumors injected in nude mice and lymph node metastasis were found more frequently [23]. Similar results were reported with VEGF-C overexpressing MDA-MB-435 [30]. In the present study, MCF7 cells overexpressing or not VEGF-C were inoculated into RAG-1-/- immunodeficient mice crossed with PAI-1 WT or PAI-1 deficient mice. In accordance with previous reports [22], [23], we confirmed the increased growth rate of VEGF-C expressing tumors. The pro-tumoral effect of VEGF-C was previously attributed to a better oxygenation due to a slight angiogenic response or a decreased intratumoral pressure because of the increased number of lymphatic vessels. It is worth noting that the mice background and the immunodeficiency rate are essential factors influencing the lymph node dissemination. Indeed, the propensity of VEGF-C expressing cells to disseminate into lymph node was higher in nude mice [23], [30] than in SCID mice [22] or RAG-1-/- mice (the present study). Since these mice differ in their B-lymphocyte status, it suggests that B lymphocytes might contribute to lymph node dissemination of cancerous cells. Accordingly, the requirement of B-lymphocytes was also observed in a lymphangiogenesis model of mycoplasma infection of the pulmonary tract [31].
###end p 53
###begin p 54
###xml 101 105 101 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-Maillard1">[10]</xref>
###xml 107 111 107 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-McMahon1">[18]</xref>
###xml 340 343 340 343 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 722 726 722 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-Almholt1">[21]</xref>
###xml 328 330 <span type="species:ncbi:10090">WT</span>
###xml 344 348 <span type="species:ncbi:10090">mice</span>
###xml 574 589 <span type="species:ncbi:10090">transgenic mice</span>
###xml 838 853 <span type="species:ncbi:10090">transgenic mice</span>
In agreement with previous studies, PAI-1 deficiency was associated with decreased tumor development [10], [18]. We further analysed the lymphatic invasion of these tumors and their dissemination into lymph nodes. Although VEGF-C expression led to an enhancement of lymphatic vessel numbers, no difference was observed in PAI-1 WT and PAI-1-/- mice. Moreover, both genotypes showed a similar rate of lymph node metastasis. These data clearly demonstrate that PAI-1 is not implicated in tumoral lymphangiogenesis. Moreover, our data are in line with a previous study on PyMT transgenic mice showing that the primary tumor growth was not significantly affected by PAI-1 deficiency and neither was the lung metastatic burden [21]. We now demonstrate that PAI-1 is dispensable for tumoral lymphangiogenesis by using the PyMT and PAI-1 double transgenic mice.
###end p 54
###begin p 55
###xml 56 60 56 60 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-Hojilla1">[32]</xref>
###xml 62 66 62 66 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-DeNardo1">[33]</xref>
###xml 185 188 185 188 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 362 366 362 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-Mancardi1">[24]</xref>
###xml 368 372 368 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-Nakamura1">[34]</xref>
###xml 532 536 532 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-PhilipJoet1">[35]</xref>
###xml 858 862 858 862 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-ChuangTsai1">[36]</xref>
###xml 864 868 864 868 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-Oda1">[37]</xref>
###xml 914 918 914 918 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-ChuangTsai1">[36]</xref>
###xml 977 981 977 981 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-Oda1">[37]</xref>
###xml 1141 1144 1141 1144 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1233 1236 1233 1236 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1539 1543 1539 1543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-Wiseman1">[38]</xref>
###xml 1719 1723 1719 1723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-Lu1">[39]</xref>
###xml 1725 1729 1725 1729 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-Ghajar1">[40]</xref>
###xml 189 193 <span type="species:ncbi:10090">mice</span>
###xml 557 561 <span type="species:ncbi:10090">mice</span>
###xml 649 651 <span type="species:ncbi:10090">WT</span>
###xml 652 656 <span type="species:ncbi:10090">mice</span>
###xml 1155 1157 <span type="species:ncbi:10090">WT</span>
###xml 1158 1162 <span type="species:ncbi:10090">mice</span>
###xml 1237 1241 <span type="species:ncbi:10090">mice</span>
Knowing that inflammation influences cancer progression [32], [33] and that lymphangiogenesis and inflammation processes are closely related, we applied a model of lymphangioma to PAI-1-/- mice. This system consists in a benign hyperplasia of lymphatic vessels induced by the injection of Freund adjuvant and is often used to isolate lymphatic endothelial cells [24], [34]. In this system, the inflammatory reaction induced by Freund adjuvant relies on the recruitment of leukocytes by cytokines secreted by cells of the peritoneum [35]. In PAI-1 deficient mice, we observed a macroscopic decrease of the lymphangioma formation as compared to PAI-1 WT mice. This effect could be ascribed to a reduction of fibrosis rather than to a decrease in lymphatic vessel recruitment. Accordingly, PAI-1 deficiency slowed down the fibrotic reaction in different models [36], [37] by accelerating plasmin-mediated proteolysis [36] or by influencing macrophage or myofibroblast recruitment [37]. The lack of PAI-1 effect on inflammation related lymphangiogenesis was further confirmed by similar injury-induced corneal lymphangiogenesis observed in PAI-1-/- and PAI-1 WT mice. The increased lymphatic vessel size observed in lymphangioma of PAI-1-/- mice is intriguing. However, note that this variation in vessel structure is associated with a reduction of matrix deposition which may influence vessel branching. Studies on mammary gland morphogenesis revealed that the collagen deposition inhibition reduced developing tubular structure bifurcations [38]. The matrix proteolytic breakdown could compromise the scaffold mechanical integrity necessary to counter endothelial cells-generated forces during the tube formation process [39], [40]. Thus, the difference in vessel structure likely relies on PAI-1-regulated fibrotic response rather than on a direct effect of PAI-1 on lymphangiogenesis.
###end p 55
###begin p 56
###xml 540 544 540 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-Andreasen1">[41]</xref>
###xml 870 878 870 878 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 883 890 883 890 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 898 902 898 902 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009653-Bruyere1">[29]</xref>
The present study using genetic approaches provide for the first time evidences that in contrast to its pivotal role in pathological angiogenesis, PAI-1 is dispensable in pathological lymphangiogenesis in tumoral situations as well as in inflammatory disorders. This clearly demonstrates that distinct molecular pathways govern angiogenesis and lymphangiogenesis and that PAI-1 plays distinct roles in the remodelling of both circulation systems in pathological conditions. Providing that PAI-1 antagonists are used to inhibit angiogenesis [41], our results reveal that this approach will not have any effect on lymphangiogenesis. Although PAI-1 is dispensable for lymphangiogenesis, it is worth noting that other proteolytic systems are mandatory for this process and particularly matrix metalloproteases such as the MMP-2 whose deficiency impairs lymphangiogenesis in in vitro and in vivo models [29].
###end p 56
###begin p 57
The authors acknowledge G. Roland, F. Olivier, I. Dasoul, E. Feyereisen, L. Poma and P. Gavitelli for their excellent technical assistance.
###end p 57
###begin title 58
References
###end title 58
###begin article-title 59
Molecular biology and pathology of lymphangiogenesis.
###end article-title 59
###begin article-title 60
Tumor-induced lymphangiogenesis: A target for cancer therapy?
###end article-title 60
###begin article-title 61
Is defective lymphatic drainage a trigger for lymphoid neogenesis?
###end article-title 61
###begin article-title 62
###xml 36 41 <span type="species:ncbi:9606">human</span>
Evolving role of uPA/uPAR system in human cancers.
###end article-title 62
###begin article-title 63
Plasminogen Activator Inhibitor-1: The expression, Biological Functions, and Effects on Tumorigenesis and Tumor Cell Adhesion and Migration.
###end article-title 63
###begin article-title 64
Plasminogen activation and cancer.
###end article-title 64
###begin article-title 65
Unexpected role of plasminogen activator inhibitor 1 in cell adhesion and detachment.
###end article-title 65
###begin article-title 66
Plasminogen activator inhibitor-1 protects endothelial cells from FasL-mediated apoptosis.
###end article-title 66
###begin article-title 67
Effect of pharmacologic plasminogen activator inhibitor-1 inhibition on cell motility and tumor angiogenesis.
###end article-title 67
###begin article-title 68
###xml 48 53 <span type="species:ncbi:9606">human</span>
Host plasminogen activator inhibitor-1 promotes human skin carcinoma progression in a stage-dependent manner.
###end article-title 68
###begin article-title 69
Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization.
###end article-title 69
###begin article-title 70
###xml 33 37 <span type="species:ncbi:10090">mice</span>
Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1.
###end article-title 70
###begin article-title 71
Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization.
###end article-title 71
###begin article-title 72
Dose-dependent modulation of choroidal neovascularization by plasminogen activator inhibitor type I: implications for clinical trials.
###end article-title 72
###begin article-title 73
###xml 44 49 <span type="species:ncbi:9606">human</span>
Antibodies to plasminogen activator inhibit human tumor metastasis.
###end article-title 73
###begin article-title 74
###xml 85 90 <span type="species:ncbi:9606">human</span>
###xml 115 119 <span type="species:ncbi:10090">mice</span>
The antibody to plasminogen activator inhibitor-1 suppresses pulmonary metastases of human fibrosarcoma in athymic mice.
###end article-title 74
###begin article-title 75
The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent.
###end article-title 75
###begin article-title 76
Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis.
###end article-title 76
###begin article-title 77
Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth.
###end article-title 77
###begin article-title 78
Tumoral and choroidal vascularization: differential cellular mechanisms involving plasminogen activator inhibitor type I.
###end article-title 78
###begin article-title 79
###xml 91 95 <span type="species:ncbi:10090">mice</span>
Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice.
###end article-title 79
###begin article-title 80
Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth.
###end article-title 80
###begin article-title 81
VEGF-C induced lymphangiogenesis is associated with lymph node metastasis in orthotopic MCF-7 tumors.
###end article-title 81
###begin article-title 82
Lymphatic endothelial tumors induced by intraperitoneal injection of incomplete Freund's adjuvant.
###end article-title 82
###begin article-title 83
Quantitative morphometry of conjunctival microcirculation in diabetes mellitus.
###end article-title 83
###begin article-title 84
Additional parameters for the morphometry of angiogenesis and lymphangiogenesis in corneal flatmounts.
###end article-title 84
###begin article-title 85
Altered expression of angiogenesis and lymphangiogenesis markers in the uninvolved skin of plaque-type psoriasis.
###end article-title 85
###begin article-title 86
Time course of angiogenesis and lymphangiogenesis after brief corneal inflammation.
###end article-title 86
###begin article-title 87
Modeling lymphangiogenesis in a three-dimensional culture system.
###end article-title 87
###begin article-title 88
Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis.
###end article-title 88
###begin article-title 89
Immune complex-dependent remodeling of the airway vasculature in response to a chronic bacterial infection.
###end article-title 89
###begin article-title 90
Inflammation and breast cancer: metalloproteinases as common effectors of inflammation and extracellular matrix breakdown in breast cancer.
###end article-title 90
###begin article-title 91
Immune cells as mediators of solid tumor metastasis.
###end article-title 91
###begin article-title 92
###xml 54 60 <span type="species:ncbi:10090">murine</span>
Inhibition of lymphangiogenesis-related properties of murine lymphatic endothelial cells and lymph node metastasis of lung cancer by the matrix metalloproteinase inhibitor MMI270.
###end article-title 92
###begin article-title 93
Fibrinolytic and inflammatory processes in pleural effusions.
###end article-title 93
###begin article-title 94
###xml 42 46 <span type="species:ncbi:10090">mice</span>
Reduction in fibrotic tissue formation in mice genetically deficient in plasminogen activator inhibitor-1.
###end article-title 94
###begin article-title 95
PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction.
###end article-title 95
###begin article-title 96
Site-specific inductive and inhibitory activities of MMP-2 and MMP-3 orchestrate mammary gland branching morphogenesis.
###end article-title 96
###begin article-title 97
Patterning mechanisms of branched organs.
###end article-title 97
###begin article-title 98
Matrix metalloproteinase control of capillary morphogenesis.
###end article-title 98
###begin article-title 99
The plasminogen activation system in tumor growth, invasion, and metastasis.
###end article-title 99
###begin p 100
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 100
###begin p 101
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was supported by grants from the European Union Framework Program projects (FP7-2007-2011 "MICROENVIMET" No 201279), the Fonds de la Recherche Scientifique Medicale, the Fonds National de la Recherche Scientifique (F.N.R.S., Belgium), the Fondation contre le Cancer, the Fonds speciaux de la Recherche (University of Liege), the Centre Anticancereux pres l'Universite de Liege, the Fonds Leon Fredericq (University of Liege), the D.G.T.R.E. from the <<Region Wallonne>>, the Interuniversity Attraction Poles Programme - Belgian Science Policy (Brussels, Belgium). FB, BD, AM and JL are recipients of a Televie-FNRS grant. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 101

